


# Evonik Vancouver Laboratories

A CDMO leader for advanced lipid nanoparticle drug delivery with significant expertise in siRNA, mRNA, peptides and high potency APIs



# Evonik Vancouver Laboratories

Best-in-class solutions for lipid-based nanoparticle drug formulations

Evonik Vancouver Laboratories is a leading technology, product and service provider of advanced lipid-based nanoparticle drug formulations.

The Evonik Vancouver site near Burnaby, British Columbia, formerly Transferra Nanosciences Inc., is a contract development and manufacturing organization (CDMO) that offers Chemistry, Manufacturing and Control (CMC) services to customers conducting pharmaceutical research and development. With proven success in moving drug candidates from the bench into clinical trials, Evonik's Burnaby site focuses on lipid nanoparticle (LNP) drug delivery systems from pre-formulation R&D services through GMP clinical trial manufacturing and commercial process development.

Evonik Health Care excels in the provision of products, services and technology for extended release drug delivery in both parenteral and oral formulation applications.

The addition of the lipid nanoparticle formulation services and LIPEX® extruder equipment of the Vancouver site continues to broaden and strengthen the array of services and products offered globally by Evonik Health Care.



## Our offering, your benefit:

### INTEGRATED FORMULATION SERVICES

- Significant experience with targeting and stabilizing oligonucleotide drugs
- Enhancement of solubility and bioavailability of high potency APIs
- Development expertise through 100+ unique formulations with our lipid nanoparticle technology
- Seamless transition from scale up through clinical manufacturing
- Comprehensive analytical services to accompany R&D, toxicology, clinical and commercial manufacturing
- LIPEX® extruders ranging from benchtop to commercial production scale

### TECHNICAL EXCELLENCE WITH RIGOROUS AND PHASE APPROPRIATE QUALITY ASSURANCE

- Quality systems around manufacturing processes subject to 25+ audits in the last 5 years
- About 50% of the audits were conducted by European Qualified Persons (QP)
- No quality system deficiencies noted by Health Canada

This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. In no event shall Evonik assume liability for damages or losses of any kind or nature that result from the use of or reliance upon this information and recommendations. EVONIK EXPRESSLY DISCLAIMS ANY REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY AND / OR FITNESS FOR A PARTICULAR PURPOSE (EVEN IF EVONIK IS AWARE OF SUCH PURPOSE) WITH RESPECT TO ANY INFORMATION AND RECOMMENDATIONS PROVIDED. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product, and does not imply that similar products could not be used. Evonik reserves the right to make any changes to the information and / or recommendations at any time, without prior or subsequent notice.

**Evonik Nutrition & Care GmbH**  
Health Care Business Line  
Pharma Polymers & Services

healthcare@evonik.com  
www.healthcare.evonik.com